Moreover, NPS-1034 resolved drug resistance caused by amplified Met and Axl gene expression in cancer cell lines [10], synergistically enhanced the efficacy of preexisting epidermal growth factor receptor tyrosine kinase inhibitor (e.g., Erlotinib and Gefitinib), downregulated oncogenic protein expressions, and promoted cell death [10]. Here, AXL is linked to cancer.